Introduction
The pathology of ischemic stroke is complex and involves a myriad of distinct molecular pathways and cellular interactions. Among these, progressive thrombus formation in the cerebral microvasculature is a key process that can cause secondary infarct growth despite successful recanalization of larger proximal brain vessels both under experimental conditions as well as in humans. 1, 2 We recently identified the intrinsic coagulation cascade as a novel and safe antithrombotic target for the prevention and treatment of acute ischemic stroke. 3 Genetic depletion or pharmacological blockade of coagulation factor XII (FXII), the origin of the intrinsic pathway, markedly reduced intracerebral thrombus formation and infarct growth in mice without increasing the risk of bleeding complications. 4, 5 Clot formation was also significantly reduced in several in vitro models of thrombosis following FXII inhibition. 5 Current pathophysiological concepts also emphasize the importance of inflammatory mechanisms in stroke. 6 The cerebral endothelium is activated early during the course of an ischemic event leading to the up-regulation of cell adhesion molecules and successive trafficking of inflammatory cells (neutrophils, macrophages, T cells) from the blood stream into the brain parenchyma. Those cells attracted from the periphery in concert with resident cell populations (endothelial cells, microglia) secrete an array of soluble immune mediators such as cytokines and chemokines that perpetuate the inflammatory response to cause direct or indirect tissue damage. In case of persisting ischemia the structural components forming the blood-brain-barrier, such as tightjunction proteins, become disengaged leading to the formation of vascular edema. 7 Edema, in turn, harms otherwise healthy brain areas by compression and is a frequent cause of delayed functional deterioration in stroke patients. Pharmacologic strategies to combat inflammation or edema formation in acute ischemic stroke are not currently available. 8 Interestingly, however, there is increasing evidence of a only.
For personal use at CLEVELAND HLTH SCI LIBR on October 30, 2012. bloodjournal.hematologylibrary.org From tightly regulated interplay between thrombotic and inflammatory mechanisms during stroke development and this 'thrombo-inflammation' might be accessible to specific therapeutic interventions. 9 High-molecular-weight kininogen (KNG) is an important constituent of the plasma contact-kinin system which represents a network of serially connected serine proteases. 10 Activation of the contact-kinin system by FXII triggers cleavage of KNG by plasma kallikrein (PK) and subsequent release of the proinflammatory peptide hormone bradykinin. The contact-kinin system occupies a central position in the pathophysiology of different neurological disease models mimicking, for example, multiple sclerosis 11 or traumatic brain injury (TBI). 12 In acute ischemic stroke activation of the contact-kinin system fosters vascular permeability and stroke-related inflammation by the formation of short-lived kinins while at the same time it is linked to thrombus formation via the FXII-driven intrinsic coagulation cascade. 4, 5, 13 Therefore, the contact-kinin system represents a promising multifunctional target for potential stroke therapies. However, to which extent the different molecular constituents of the contact-kinin system contribute to stroke development has been largely unknown, a situation resulting from the lack of appropriate transgenic mouse models.
To address this shortcoming, we analyzed functional outcome, thrombus formation and inflammatory processes in models of acute ischemic stroke in KNG-deficient mice recently described by our group. 14 only.
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Methods
A detailed description of the methods, the surgical procedures and the stroke study population is provided in the Supplemental Material.
Ischemia model. A total of 298 mice (149 C57Bl/6 wild-type mice and 149 Kng -/-mice) were included in the study which was conducted in accordance with institutional guidelines (University of Würzburg, Germany) for the use of experimental animals, and the protocols were approved by governmental authorities (Regierung von Unterfranken, Würzburg, Germany). Kng -/-mice were described previously 14 and
were backcrossed for more than 10 generations into a C57Bl/6 background. Ageand sex-matched C57Bl/6 mice (Charles River) served as controls. If not otherwise mentioned, we performed 60 min transient middle cerebral artery occlusion (tMCAO) in 6 weeks old male mice weighing 20 -25 g, as described. 4, 15 To exclude age-or gender-specific effects, 6 month old male or 6 week old female mice were used in some subgroups. For permanent MCAO (pMCAO) the occluding filament was left in situ until sacrificing the animals. Mice were controlled for physiological parameters that can critically affect stroke outcome (cerebral blood flow, blood pressure, heart rate, brain structure, blood gases) ( Supplementary Figures 1 -3 
Magnetic resonance imaging (MRI).
To analyze infarct dynamics and to scan for possible intracerebral bleeding serial stroke assessment by MRI was performed 24h, and again 7d after tMCAO on a 1.5 Tesla unit (Vision, Siemens) using T2-w imaging sequences and blood-sensitive T2-w gradient echo constructed interference in steady state (CISS) sequences as described.
4,22
Laser Doppler flowmetry. Laser Doppler flowmetry (Moor Instruments) was used to monitor regional cerebral blood flow (CBF) in the territory of the right middle cerebral artery at baseline (before ischemia), immediately after insertion of the occluding filament (ischemia), immediately after removal of the occluding filament (reperfusion) and again 12h and 24h after reperfusion.
17
Real-time PCR studies. Real-time PCR (StepOnePlus TM Real-Time PCR System, Applied Biosystems) was used to determine relative gene expression levels of inflammatory markers in the ischemic cortices and basal ganglia as described. 13 only.
8
Determination of blood-brain-barrier damage and brain edema. Blood-brainbarrier damage was quantified by photometric measurement (Fluoroskan Ascent, Thermo Scientific) of Evan's Blue dye (2% in 100 µl PBS i. v., Sigma) leaking into the brain parenchyma. 13 The free water content of the brains (edema) was calculated from the brains' wet/dry weights.
13
Immunohistology. Staining protocols for immune cells, fibrin(ogen), occludin and the assessment of the thrombosis index are described in the Supplemental Material.
Western blot. Immunoreactivity for fibrin(ogen) (anti-Fibrin(ogen) pAb 1:500, cross reactive for fibrin and fibrinogen, Acris Antibodies) and occludin (anti-occludin pAB 1:1000, Abcam) was detected by Western blot and quantified by densitometry. For the detection of KNG a murine monoclonal antibody to the light chain of high molecular weight KNG was used (anti-KNG mAb 1:100, Clone C11C1, Abcam). Actin served as loading control for all Western blot experiments.
Statistics
All results were expressed as mean ± standard error of the mean (s.e.m.) except for ordinal functional outcome scales which were depicted as scatter plots including median with the 25% percentile and the 75% percentile given in brackets in the text.
Numbers of animals (N = 10) necessary to detect a standardized effect size on infarct volumes ≥ 
Results
Kininogen deficiency provides sustained protection from ischemic stroke
In the first set of experiments we investigated the protein expression of KNG in the ischemic brains from wild-type mice with induced focal cerebral ischemia or shamoperated controls by immunoblot (Figure 1 ). Here, we chose a model of ischemic stroke in which mice are subjected to transient middle cerebral artery occlusion (tMCAO). This model induces a rapid and strong activation of the contact-kinin system leading to local inflammation and progressive microvascular thrombosis within the brain. 4, 13 While native KNG was present in the brains of sham-operated mice, it was strongly down-regulated in the ischemic (ipsilateral) and contralateral hemispheres of mice with cerebral ischemia 24h after tMCAO ( Figure 1 ).
Downregulation of KNG also in the contralateral hemispheres was probably due to excessive ipsilateral infarct-related edema formation and subsequent compression of essentially 'healthy' (contralateral) brain regions under the experimental condition of 60 min tMCAO (see below). Conversely, cleaved KNG which is formed when bradykinin is released from native KNG by plasma kallikrein was abundant after stroke but was absent in brains from sham-operated animals ( Figure 1 ). This (Figure 2A, B) .
Kng -/-mice are unable to produce bradykinin and blood bradykinin levels are below the detection limit in these mutants. 14 To address whether bradykinin released from KNG is indeed a critical mediator of neuronal damage after stroke, we reconstituted only.
1
Kng
-/-mice with bradykinin. Since bradykinin has a very short half life time in the blood and in order to obtain maximum bradykinin concentrations directly within the CNS, we decided to inject bradykinin intrathecally immediately after the induction of tMCAO and again at the time point of reperfusion (100 ng per injection).
18,19
Reconstitution of Kng -/-mice with bradykinin rescued the phenotype and induced infarct volumes (121.6 ± 13.0 mm Gender can significantly influence stroke outcome in rodents. 23 Therefore, we also subjected female Kng -/-mice to 60 min tMCAO. Consistent with the results in male mice, KNG-deficient female mice also developed significantly smaller infarctions (P < 0.001) and less severe neurological deficits (P < 0.05) compared to female controls ( Figure 2A , B).
Ischemic stroke usually is a disease of the elderly and consequently, it is recommended to verify any stroke-protective effects observed in young adult laboratory animals also in an older cohort. 23 Indeed, 6 months old Kng -/-mice also had significantly smaller stroke volumes (P < 0.05) and a better functional outcome (P < 0.05, grip test score) compared to age-matched controls thereby confirming our results in young animals ( Figure 2A , B).
We also determined the functional outcome and mortality of 6 weeks old male Kng -/-mice and matched wild-type controls over a longer time period after ischemic stroke.
Four days after 60 min tMCAO, 5/10 wild-type mice (50%) had died, consistent with previous reports 17 ( Figure 2C ). In contrast, 10/10 Kng -/-mice (100%) survived until day 4, and 7/10 (70%) were still alive after 8 days (P = 0.0075). In line with these findings, KNG-deficient mice showed significantly smaller strokes (P < 0.001) and a better Bederson score (P < 0.05) than controls on day 3 ( Figure 2A , B). These only.
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According to current experimental stroke guidelines, 23 any protective effect requires evaluation in models of both transient and permanent ischemia. We therefore subjected Kng -/-mice to filament-induced permanent middle cerebral artery occlusion (pMCAO), a procedure in which no tissue reperfusion occurs. In contrast to the striking effects observed after tMCAO, KNG deficiency did not significantly influence stroke size (P > 0.05) or neurological outcome (P > 0.05) 24h after pMCAO ( Figure   2A , B).
KNG deficiency reduces thrombosis after stroke without increasing the risk of intracerebral hemorrhage
It has been shown that the Kng -/-mice used in this study produce less thrombi in models of artificial vessel wall injury 14 which is in line with the prothrombotic properties of other members of the contact-kinin system such as FXII. Hypointense areas, which typically indicate hemorrhage, were absent in all animals, supporting the notion that KNG deficiency does not increase the risk of infarct or reperfusion-associated bleeding compared with wild-type control mice, even at more advanced stages of infarct development.
KNG deficiency reduces blood-brain-barrier damage and inflammation after stroke
The contact-kinin system is also critically involved in the regulation of vascular permeability and inflammatory processes upon tissue injury including ischemic stroke. 13 One central step in this process is the release of the proinflammatory peptide hormone bradykinin from KNG following plasma kallikrein activation.
Consequently, the extent of blood-brain-barrier damage and edema formation was assessed after focal cerebral ischemia. On day 1 after tMCAO the integrity of the underlining the specificity of this detrimental bradykinin effect in stroke ( Figure 5A ). Figure 5C ). Although endothelin-1 transcripts were also induced in the brains of KNG-deficient mice, expression levels remained significantly lower than in wild-type mice both in the cortex (P < 0.05) and in the basal ganglia (P < 0.001).
In line with a blood-brain-barrier destabilizing effect of KNG the tight junction protein occludin was strongly downregulated in cerebral vessels of wild-type mice but was preserved in Kng -/-mice 24h after tMCAO, as demonstrated by immunohistochemistry ( Figure 5D ). To quantify occludin protein expression in more detail we also performed Western blot analysis. Again, occludin immunoreactivity on day 1 after tMCAO was significantly weaker in the ischemic cortices (P < 0.05) and basal ganglia (P < 0.05) of wild-type mice compared with sham operated mice while no significant downregulation of occludin could be observed in KNG-deficient mice (P > 0.05) ( Figure 5E ).
As a next step we analyzed the gene expression profiles of several prototypic proand anti-inflammatory cytokines in the brains of wild-type mice and Kng -/-mice 24h after tMCAO ( Figure 6A ). The amount of IL-1β mRNA in the infarcted cortices and basal ganglia was strongly elevated in both groups compared with sham operation (P < 0.0001) but induction was far lower in mice lacking KNG (P < 0.0001). In contrast, the number of TNFα transcripts did not differ between wild-type mice and Kng -/-mice only.
For We consider the results described here to be novel for a number of reasons. First, several reports have suggested that KNG exerts antithrombotic effects. 26-28 However, our studies clearly demonstrate that the absence of KNG protects from thrombosis in the tMCAO model. The exact reasons for these divergent findings are unclear so far.
However, differences in the thrombosis models (artificial vessel wall injury models only.
For
versus in vivo stroke models) and animal species (rats versus mice) used probably play a role. Second, this apparent contradiction suggests potentially novel mechanisms by which KNG promotes thrombosis, which at this point are unknown.
While these may involve FXI, which binds high-molecular-weight KNG, 29-31 whether these interactions alone account for KNG's prothrombotic activity is uncertain. Third, the degree of neuroprotection caused by KNG depletion is remarkable, and exceeds that observed in other reports of cerebral ischemia in animals deficient in members of the kallikrein-kinin system. 4, 32 41 We have demonstrated that KNG is consumed in the cerebral circulation or tissue following brain ischemia/reperfusion (I/R) in wild-type mice. KNG cleavage by plasma kallikrein reflects activation of the kallikrein-kinin system after stroke and subsequent bradykinin formation and can also be observed in I/R models in other organ systems such as the heart (myocardial infarction) 42 or after brain trauma. 43 Importantly, blood KNG levels are also reduced in human stroke patients.
44
In the absence of substrate, Kng -/-mice are completely unable to produce bradykinin. 14 This lack of bradykinin most likely underlies the strong anti-inflammatory phenotype observed in the context of brain ischemia. The blood-brain-barrier was highly maintained in the absence of KNG after stroke, an effect that could be ascribed to preserved occludin expression. As a consequence mice without KNG developed significantly less brain edema which is known to be a frequent cause of secondary infarct growth and deterioration of neurological symptoms. Importantly, reconstitution of Kng -/-mice with bradykinin fully restored edema formation after tMCAO underpinning the specificity of this detrimental bradykinin effect. By analogy, degradation of occludin and other tight junction proteins via a bradykinin-dependent pathway destabilized the blood-brain-barrier in different tumor models. 45 Endothelin-1 levels were also lower in the ischemic brains of Kng -/-mice compared with controls. Finally, the expression of soluble immune mediators was altered in the absence of KNG. KNG mutant mice expressed less IL-1β in the cortices and basal ganglia after tMCAO, whereas the amount of TGFβ-1 was increased compared to wild-type controls. IL-1β is regarded a prototypic proinflammatory cytokine known to aggravate ischemic brain damage. 52 In contrast, TGFβ-1 exerts pleiotropic immune functions and has been shown to mediate neuroprotection during stroke.
The 24h gap between the onset of ischemia and the first outcome analysis to some extent limits the interpretation of our findings. In particular, the question of whether with KNG or bradykinin fully restored thrombus formation and edema formation clearly argues for a causative rather than a merely correlative relationship.
Another unresolved issue is whether KNG acts detrimental in tMCAO mainly during the phase of ischemia or during reperfusion. The observation that protection from stroke in Kng -/-mice was lost after permanent MCAO suggests that KNG is of particular relevance for mediating reperfusion injury. Of note, the findings reported here are in full accordance with our studies in FXII-deficient mice which are likewise protected from transient but not permanent ischemia. 53 In these mice, restoration of blood flow in the middle cerebral artery enhanced cortical reperfusion between 2h and 24h as assessed by serial CBF measurements and this effect was related to reduced microvascular thrombosis. 4, 53 However, one has to bear in mind that permanent ischemia in contrast to transient ischemia represents a maximal noxious stimulus to the brain and therefore, any results obtained in these two stroke models cannot be easily compared.
The phenotype of Kng -/-mice reported here is consistent with the phenotype of bradykinin receptor B1 (B1R)-deficient mice. B1R is another key member of the kallikrein-kinin-system which acts downstream of KNG. Blocking of B1R dramatically reduced inflammatory processes and edema formation in models of acute ischemic stroke 13 , traumatic brain injury 12 and multiple sclerosis. 11 The corresponding findings in different mouse models bearing genetic defects in the contact-kinin system suggest that thrombosis and inflammation are closely intertwined during focal cerebral ischemia. This goes congruent with the novel concept of ischemic stroke being a 'thrombo-inflammatory' disease rather than a pure vessel-occlusive disease. 9 In summary, inhibition of KNG prevents ischemic neurodegeneration by combined antithrombotic and anti-inflammatory mechanisms. Importantly, neuroprotection through targeted depletion of KNG did not increase bleeding after ischemic stroke.
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Blocking of distinct members of the kallikrein-kinin-system has the potential to become an effective and safe strategy to combat this devastating neurologic disorder and other cardiovascular diseases such as myocardial infarction. However, the true pathophysiological relevance of the kallikrein-kinin system in stroke patients still needs to be established and findings from animal studies should not be uncritically transferred to the human situation. Moreover, additional mechanisms than those 0.0001, **P < 0.001, ns: not significant, 2-way ANOVA followed by Bonferroni's multiple comparison test compared with WT mice or Kng -/-mice. Student's t-test. c, ***P < 0.0001, **P < 0.001, *P < 0.05, ## P < 0.001, # P < 0.05, 1-way ANOVA followed by Bonferroni's multiple comparison test compared with shamoperated mice (* symbol) or WT mice ( # symbol). e, *P < 0.05, 2-way ANOVA, followed by Bonferroni's multiple comparison test, group comparisons as indicated in the figure. 
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